Reuters logo
BRIEF-Jazz Pharmaceuticals comments on FDA nod for generic version of Xyrem
January 18, 2017 / 11:27 AM / 9 months ago

BRIEF-Jazz Pharmaceuticals comments on FDA nod for generic version of Xyrem

Jan 18 (Reuters) - Jazz Pharmaceuticals Plc

* Jazz Pharmaceuticals says it will evaluate FDA’s waiver of requirement for a single, shared system rems in connection with approval of a generic version of Xyrem

* Says it will evaluate whether FDA’s waiver meets conditions for such a waiver under applicable law

* Says it intends to evaluate potential challenges to FDA's waiver decision on the generic version of Xyrem Source text: bit.ly/2jmWQ8O Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below